The expression profile of functional regulatory T cells, CD4 +CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease: ORIGINAL ARTICLE

Clinical and Experimental Immunology

Volumn 156, Issue 2, 2009, Pages 320-327

  Kamikozuru, K ^b   Fukunaga, K ^a,b   Hirota, S ^a   Hida, N ^b   Ohda, Y ^b   Yoshida, K ^b   Yokoyama, Y ^b   Tozawa, K ^b   Kawa, K ^b   Iimuro, M ^c   Nagase, K ^b   Saniabadi, A R ^b   Nakamura, S ^b   Miwa, H ^b   Matsumoto, T ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Department of Lower Gastroenterology ^*  (Japan)

^c Endoscopic Center   (Japan)

Author keywords

Adsorptive granulocyte monocyte apheresis; CD4+CD25 high+; FoxP3+; Treg; UC

Indexed keywords

BASILIXIMAB; CD4 ANTIBODY; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MESALAZINE; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CD4+ CD25+ FOXP3+ REGULATORY T LYMPHOCYTE; CELL COUNT; CELL THERAPY; CLINICAL ARTICLE; COLON RESECTION; CONTROL GROUP; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; INTESTINE MUCOSA; MALE; MONOCYTE; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA; REGULATORY T LYMPHOCYTE; REMISSION; SIGMOIDOSCOPY; T LYMPHOCYTE SUBPOPULATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADSORPTION; ADULT; ANTIGENS, CD4; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GLUCOCORTICOIDS; GRANULOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKAPHERESIS; MALE; MIDDLE AGED; MONOCYTES; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 64649100879     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03904.x     Document Type: Article

References (29)

1. Allison MC, Dhillon AP, Lewis WG, eds. Inflammatory bowel disease. London : Mosby, 1998 : 9 95.
2. Gismera CS, Aladrén BS. Inflammatory bowel disease: a disease(s) of modern times? Is incidence still increasing? World J Gastroenterol 2008 14 : 5491 98.
3. +CD25+ regulatory T cells for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2005 5 : 451 62.
4. Markovic-Plese S, Cortese I, Wandinger KP et al. CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest 2001 108 : 1185 94.
5. Gershon RK. A disquisition on suppressor T cells. Transplant Rev 1975 26 : 170 85.
6. +CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001 182 : 18 32.
7. Curotto de Lafaille MA, Lafaille JJ. CD4+ regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002 14 : 771 8.
8. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O et al. CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001 166 : 3008 18.
9. + T-cell subsets in patients with ulcerative colitis: modified by selective leucocytapheresis. Dig Dis Sci 2007 52 : 2725 31.
10. Saniabadi AR, Hanai H, Bjarnason I et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apheres Dial 2003 7 : 48 59.
11. Saniabadi AR, Hanai H, Fukunaga K et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Apher Sci 2007 37 : 191 200.
12. Muratov V, Saniabadi A, Lofberg R et al. Downregulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorect Dis 2006 21 : 493 504.
13. Hanai H. Position of selective leucocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006 12 : 7568 77.
14. Yamamoto T, Saniabadi AR, Umegae S et al. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006 12 : 719 26.
15. Hanai H, Watanabe F, Yamada M et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004 99 : 1532 8.
16. Lichtiger S, Present DH, Kornbluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 5.
17. Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001 16 : 1 9.
18. Hiraishi K, Takeda Y, Shiobara N et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003 7 : 334 40.
19. Rachmilewitz D, on behalf of an International Study Group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ 1989 298 : 82 6.
20. Powrie F, Read S, Mottet C et al. Control of immune pathology by regulatory T cells. Novartis Found Symp 2003 252 : 92 8.
21. Liu H, Hu B, Xu D et al. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003 171 : 5012 17.
22. Sitohy B, Hammarström S, Danielsson A et al. Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action. Clin Exp Immunol 2008 151 : 326 33.
23. Fahlen L, Read S, Gorelik L et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 2005 201 : 737 46.
24. Singh B, Read S, Asseman C et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001 182 : 190 200.
25. Maul J, Loddenkemper C, Mundt P et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005 128 : 1868 78.
26. Baecher-Allan C, Brown JA, Freeman GJ et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001 167 : 1245 53.
27. Huber S, Schramm C, Lehr HA et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004 173 : 6526 31.
28. Melgar S, Yeung MM, Bas A et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol 2003 134 : 127 37.
29. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001 167 : 1137 40.